Madrigal’s Rezdiffra tops $1B run-rate in MASH, but losses and rising GLP-1/FGF21 competition may cap upside into 2026. See ...
Madrigal Pharmaceuticals provided an update on its financial performance, revealing preliminary fourth-quarter and full-year 2024 net sales for Rezdiffra™ (resmetirom) projected between $100 million ...
The New Year's Champagne turned flat for Madrigal Pharmaceuticals ( MDGL 5.01%) on Tuesday. Investors traded out of the ...
Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectivelyAs of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents, ...
CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...
Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals ...
Hosted on MSN
Goldman Sachs maintains Buy on Madrigal shares as Rezdiffra drives strong patient adoption
On Thursday, Goldman Sachs reaffirmed their positive stance on Madrigal Pharmaceuticals (NASDAQ:MDGL), maintaining a Buy rating and a price target of $530.00. Currently trading at $274.41, the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback